Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. PayPal (PYPL) upgraded to Buy from Hold at Stifel with analyst Scott Devitt saying he believes PayPal is in the early stages of transforming from an online checkout company to a global payments platform. 2. Novartis (NVS) upgraded to Neutral from Underperform at Credit Suisse. 3. Colgate-Palmolive (CL) upgraded to Buy from Hold at Argus analyst John Eade saying the stock price has been dragged down to a point where the shares "offer value" given the "above market average" dividend payout and the first EPS beat in 4 quarters in the most recent earnings results. 4. Best Inc. (BSTI) upgraded to Buy from Neutral at Citi. 5. Loma Negra (LOMA) upgraded to Outperform from Market Perform at Itau BBA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage,

Notable companies reporting before tomorrow's open, with earnings consensus, include Exxon Mobil (XOM), consensus $2.20... Chevron (CVX), consensus $2.87... AbbVie (ABBV), consensus $2.23... HCA Healthcare (HCA), consensus $5.01... Colgate-Palmolive (CL), consensus 81c... Charter (CHTR), consensus $7.92... AutoNation (AN), consensus $4.27.

DMG Blockchain Solutions (DMGGF) announced a strategic collaboration with PayPal (PYPL) and Energy Web to explore ways to decarbonize the Bitcoin blockchain. The companies are working together on developing methods for transacting on the Bitcoin network which would expand its use as a carbon neutral payment rail, thus advancing its application. DMG, Energy Web, and PayPal are working together to publish a research paper, which we collectively believe will benefit users of the Bitcoin network who would like to take advantage of carbon neutral options in their transactions. PayPal, with its focus on developing its bitcoin payment rail, has been a leader in new payment technologies with the introduction of its enhanced services by integrating blockchain technology, launching the PayPal USD stablecoin with Paxos Trust Company in August 2023 for efficient transactions.

TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.